Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (161-170 of 250) with videos related to

Pageof 25
Sort By:
Cancer Chemotherapy and Pharmacology|June 10, 2017
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patientsBum Jun Kim, Jaewon Hyung, Changhoon Yoo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse eventsChanghoon Yoo, Seonggyu Byeon, Yeonghak Bang, et al.
The British Journal of Surgery|August 11, 2021
Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survivalWoohyung Lee, Minyoung Oh, Jae Seung Kim, et al.
Gastroenterology|August 27, 2018
Association Between Expression Level of PD1 by Tumor-Infiltrating CD8<sup>+</sup> T Cells and Features of Hepatocellular CarcinomaHyung-Don Kim, Gi-Won Song, Seongyeol Park, et al.
Anticancer Research|March 28, 2023
Identification of Atezolizumab Plus Bevacizumab Prognostic Index <i>via</i> Recursive Partitioning Analysis in HCC: The ABE IndexMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Journal of Cancer Research and Clinical Oncology|March 27, 2023
Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinomaYoon Jung Jang, Eo Jin Kim, Hyung-Don Kim, et al.
Targeted Oncology|December 28, 2025
Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic PotentialYeokyeong Shin, Jinho Shin, Hyehyun Jeong, et al.
Journal for Immunotherapy of Cancer|March 3, 2025
Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancerHyung-Don Kim, Seyoung Jung, Yeong Hak Bang, et al.
Hepatology (Baltimore, Md.)|June 14, 2024
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trialDo-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2013
Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101)Yoon-Koo Kang, Jeong Hwan Yook, Heung-Moon Chang, et al.
Pageof 25

Showing results (161-170 of 250) with videos related to

Sort By:
Pageof 25
Cancer Chemotherapy and Pharmacology|June 10, 2017
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patientsBum Jun Kim, Jaewon Hyung, Changhoon Yoo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse eventsChanghoon Yoo, Seonggyu Byeon, Yeonghak Bang, et al.
The British Journal of Surgery|August 11, 2021
Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survivalWoohyung Lee, Minyoung Oh, Jae Seung Kim, et al.
Gastroenterology|August 27, 2018
Association Between Expression Level of PD1 by Tumor-Infiltrating CD8<sup>+</sup> T Cells and Features of Hepatocellular CarcinomaHyung-Don Kim, Gi-Won Song, Seongyeol Park, et al.
Anticancer Research|March 28, 2023
Identification of Atezolizumab Plus Bevacizumab Prognostic Index <i>via</i> Recursive Partitioning Analysis in HCC: The ABE IndexMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Journal of Cancer Research and Clinical Oncology|March 27, 2023
Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinomaYoon Jung Jang, Eo Jin Kim, Hyung-Don Kim, et al.
Targeted Oncology|December 28, 2025
Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic PotentialYeokyeong Shin, Jinho Shin, Hyehyun Jeong, et al.
Journal for Immunotherapy of Cancer|March 3, 2025
Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancerHyung-Don Kim, Seyoung Jung, Yeong Hak Bang, et al.
Hepatology (Baltimore, Md.)|June 14, 2024
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trialDo-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2013
Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101)Yoon-Koo Kang, Jeong Hwan Yook, Heung-Moon Chang, et al.
Pageof 25